血清标记物预测免疫检查点抑制剂治疗晚期非小细胞肺癌疗效的研究进展  

Progress in the Study of Serum Markers to Predict the Efficacy of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer

作　　者：李颖 田绍东 向明钧[1] 唐红兰 

机构地区：[1]吉首大学医学院,湖南 吉首 [2]湖南医药学院总医院肿瘤中心,湖南 怀化

出　　处：《临床医学进展》2024年第9期917-924,共8页Advances in Clinical Medicine

摘　　要：免疫检查点抑制剂在晚期非小细胞肺癌中的应用显著提高了患者的生存获益,但是现在临床上没有明确对于免疫治疗疗效预测的标记物,常见的PDL1、CTLA-4只能通过组织活检获得,如果能证明外周血相关指标对于疗效的预测,会更简便或者与组织学综合考量后预测价值更高。本文将从血清标记物对免疫检查点抑制剂治疗晚期非小细胞肺癌预后基线及动态监测的相关研究进展进行综述。The application of immune checkpoint inhibitors in advanced non-small cell lung cancer has significantly improved the survival benefits of patients. However, there are no clear markers for predicting the efficacy of immunotherapy in clinical practice, and common PDL1 and CTA4 can only be obtained through tissue biopsy. If the prediction of efficacy of peripheral blood related indicators can be proved, the clinical curative effect can be more easily and dynamically predicted, or the predictive value of peripheral blood indicators combined with histology may be higher. This article reviews the progress of serum markers in baseline and dynamic monitoring of the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.

关 键 词：非小细胞肺癌 免疫检查点抑制剂 外周血标记物 

分 类 号：R73[医药卫生—肿瘤]